Thyroid Fine Needle Biopsy and Impact on Pain and Diagnostic Adequacy (THY-BPSY)

July 1, 2026 updated by: Mehmet Yağtu, MD, Izmir Ataturk Training and Research Hospital

Prospective Randomized Trial of 21G Versus 27G Needles for Ultrasound-Guided Thyroid FNA: Impact on Pain and Diagnostic Adequacy

This randomized study compares patient pain and comfort during ultrasound-guided thyroid fine needle biopsy using 21-gauge versus 27-gauge needles. Patients with thyroid nodules were randomly assigned to one of two needle sizes. Pain intensity was measured immediately after the procedure using a 0-100 Visual Analog Scale. The study was conducted at İzmir Atatürk Training and Research Hospital between January 2024 and March 2024. The aim is to determine which needle size causes less pain and better patient comfort during the biopsy procedure.

Study Overview

Detailed Description

Material and methods Study Design and Ethics This prospective, randomized, single-blind clinical trial was conducted at the Radiology Department of İzmir Katip Çelebi University Atatürk Training and Research Hospital between Januray 2024 and March 2024. The study protocol was approved by the Institutional Review Board of İzmir Katip Çelebi University (IRB No: 0001/2024, approval date: 18.01.2024) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The trial was registered prior to patient enrollment. Written informed consent was obtained from all participants after explaining the procedure, potential risks, and benefits.

Patient Selection Consecutive patients referred for ultrasound-guided thyroid fine-needle biopsy (FNB) were screened for eligibility. Inclusion criteria were: (1) age ≥18 years; (2) presence of at least one thyroid nodule with maximum diameter ≥10 mm meeting American Thyroid Association 2015 guidelines for FNB; (3) nodule with entirely intrathyroidal location confirmed by ultrasound. Exclusion criteria were: (1) coagulopathy defined as INR >1.5 or platelet count <50,000/μL; (2) use of anticoagulant or antiplatelet agents within 7 days prior to procedure; (3) prior thyroid surgery, radioiodine therapy, or external beam radiation to the neck; (4) substernal extension of goiter preventing safe access; (5) pregnancy; (6) inability to understand or complete the Visual Analog Scale. A total of 159 patients with 159 dominant nodules were enrolled. Each patient underwent FNB of a single nodule; if multiple nodules were present, the most suspicious nodule based on ACR TI-RADS criteria was selected.

Randomization and Blinding Eligible patients were randomly assigned in a 1:1 ratio to undergo FNB with either a 21-gauge (21G) or 27-gauge (27G) needle. Randomization was performed using a computer-generated permuted block sequence with a block size of 4 to ensure balanced allocation. Allocation concealment was maintained using sequentially numbered, sealed, opaque envelopes opened by a study nurse immediately before the procedure. Patients were blinded to the needle gauge assignment. Due to the visual difference in needle diameter, the performing radiologist could not be blinded. All cytopathological specimens were evaluated by two board-certified cytopathologists who were blinded to the needle gauge used.

FNB Procedure All biopsies were performed by a single fellowship-trained interventional radiologist with 12 years of experience in thyroid FNB (>2500 procedures) to minimize operator-dependent variability. Patients were positioned supine with mild neck hyperextension. After skin disinfection with 70% isopropyl alcohol, a high-resolution ultrasound system (Samsung HS50, Seoul, South Korea) equipped with a 12-15 MHz linear transducer was used for real-time guidance. No local anesthesia or skin infiltration was administered, consistent with routine clinical practice at our institution. Under sterile conditions, a 21G (0.8 × 40 mm) or 27G (0.4 × 40 mm) needle was inserted using a freehand capillary technique without aspiration. The needle tip was advanced to the center of the target nodule, followed by rapid back-and-forth movements for 5-10 seconds using wrist motion only. Material was expelled onto glass slides for smear preparation and into formalin for cell block. A single pass was routinely performed; a second pass was permitted only if the operator visually assessed the specimen as macroscopically inadequate. The total number of passes was recorded for each patient.

Outcome Assessment The primary outcome was patient-reported pain intensity measured immediately after needle withdrawal. Within 5 minutes post-procedure, while still in the supine position, each patient was asked to mark their pain level on a 100-mm horizontal Visual Analog Scale (VAS) anchored by "0 = no pain" and "100 = worst imaginable pain." The distance from 0 to the patient's mark was measured in millimeters. Secondary outcomes included: (1) Diagnostic adequacy, defined as satisfactory for evaluation per The Bethesda System for Reporting Thyroid Cytopathology, determined by blinded cytopathologists; (2) Number of needle passes per nodule; (3) Complications, categorized as minor (self-limited hematoma <2 cm, transient vasovagal reaction) or major (hematoma requiring intervention, recurrent laryngeal nerve injury, tracheal puncture). Nodule characteristics including maximum diameter, echotexture ( Hypoechoic, Heterogeneous, Hyperechoic) were recorded pre-procedure.

Sample Size Calculation and Statistical Analysis Sample size was calculated based on the primary outcome. Assuming a clinically significant difference of 10 mm on the VAS, a standard deviation of 22 mm from pilot data, a two-sided α of 0.05, and power of 80%, 77 patients per group were required. To compensate for an anticipated 5% dropout rate, 159 patients were enrolled. Data normality was evaluated using the Shapiro-Wilk test. Continuous variables were expressed as mean ± standard deviation or median (interquartile range) and compared using the independent samples t-test or Mann-Whitney U test, as appropriate. Categorical variables were compared using the χ² test or Fisher's exact test. Correlation between VAS score and continuous variables was assessed using Spearman's rank correlation coefficient. Multivariable linear regression analysis was performed to identify independent predictors of post-procedural pain. All analyses were conducted using IBM SPSS Statistics version 27.0 (IBM Corp., Armonk, NY, USA). A two-tailed P-value <0.05 was considered statistically significant.

Study Type

Interventional

Enrollment (Actual)

169

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Izmir, Turkey (Türkiye), 35620
        • İzmirAtatürk Training and Education Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Thyroid nodules requiring ultrasound-guided FNB with a maximum diameter ≥3 mm,
  • Intraglandular nodules with relatively central location within the thyroid gland

Exclusion Criteria:

  • Patient refusal to provide informed consent,
  • History of bleeding tendency or use of anticoagulant medication,
  • Substernal or subclavicular localization of the lesion in cases of large goiter.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 21-gauge needle group
Patients received ultrasound-guided thyroid fine needle biopsy using 21-gauge needle
4. Ultrasound-guided fine needle biopsy performed using a 21-gauge needle for thyroid nodule cytology
Experimental: 27-gauge needle group
Patients received ultrasound-guided thyroid fine needle biopsy using 27-gauge needle
Ultrasound-guided fine needle biopsy performed using a 27-gauge needle for thyroid nodule cytology

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain score immediately after biopsy
Time Frame: Immediately after the procedure
Pain intensity measured using 0-10 Visual Analog Scale (VAS) immediately after completion of ultrasound-guided thyroid fine needle biopsy. Higher scores indicate worse pain
Immediately after the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 19, 2023

Primary Completion (Actual)

March 30, 2024

Study Completion (Actual)

March 31, 2024

Study Registration Dates

First Submitted

June 22, 2026

First Submitted That Met QC Criteria

July 1, 2026

First Posted (Actual)

July 6, 2026

Study Record Updates

Last Update Posted (Actual)

July 6, 2026

Last Update Submitted That Met QC Criteria

July 1, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 0001-2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Nodular Disease

Clinical Trials on Thyroid fine needle biopsy with 21-gauge needle

3
Subscribe